Philogen S.p.A. (BIT:PHIL)

Italy flag Italy · Delayed Price · Currency is EUR
23.20
-0.10 (-0.43%)
Jan 2, 2026, 5:35 PM CET
18.97%
Market Cap938.16M
Revenue (ttm)84.66M
Net Income (ttm)45.91M
Shares Out40.26M
EPS (ttm)1.14
PE Ratio20.39
Forward PE5.94
Dividendn/a
Ex-Dividend Daten/a
Volume11,398
Average Volume31,968
Open23.60
Previous Close23.30
Day's Range23.20 - 23.60
52-Week Range16.50 - 27.80
Beta0.16
RSI45.88
Earnings DateMar 27, 2026

About Philogen

Philogen S.p.A., a biotechnology company, develops drugs for oncology and chronic inflammatory diseases in Switzerland and the European Union. The company develops Nidlegy, a combination of the immunocytokines L19IL2 and L19TNF, which is in Phase III trial for the intralesional treatment of locoregional melanoma and non-melanoma skin cancers; Fibromun, a human immunomodulatory product consisting of L19 antibody and TNF in Phase III trial to treat soft tissue sarcoma, leiomyosarcoma, and glioma; and Darleukin (L19IL2), a human immunostimulatory ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1996
Employees 183
Stock Exchange Borsa Italiana
Ticker Symbol PHIL
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.